Medicine and Dentistry
Prostate Cancer
100%
Prostate Specific Membrane Antigen
54%
Neoplasm
50%
Fluorine-18
49%
Kidney Tumour
48%
Clear Cell Renal Cell Carcinoma
42%
Positron Emission Tomography
40%
Positron Emission Tomography-Computed Tomography
34%
Biopsy
32%
Partial Nephrectomy
31%
Radioactive Tracer
25%
Prostate Biopsy
24%
Disease
19%
Positron Emission Tomography
18%
Prostatectomy
17%
Molecular Imaging
16%
Radical Nephrectomy
14%
Computer Assisted Tomography
13%
Prostate Specific Antigen
13%
Malignant Neoplasm
12%
Surgery
12%
Metastatic Carcinoma
12%
Methoxy Isobutyl Isonitrile Technetium Tc 99m
12%
Single Photon Emission Computed Tomography-Computed Tomography
11%
Magnetic Resonance Imaging
11%
Risk Stratification
10%
Inferior Vena Cava
9%
Diagnosis
9%
Retroperitoneal Lymph Node Dissection
8%
Radiation Therapy
8%
Catheter Ablation
8%
Circulating Tumor Cell
8%
Tumor Thrombus
8%
Health Care Cost
8%
Nephrectomy
8%
Bladder Cancer
8%
Overall Survival
8%
Conventional Imaging
7%
Cancer
7%
Systematic Review
7%
Biochemical Recurrence
7%
Pelvis
7%
Multiparametric Magnetic Resonance Imaging
7%
Meta-Analysis
6%
Recurrent Disease
6%
Lymph Node
6%
Surgeon
6%
Transitional Cell Carcinoma
5%
Urologist
5%
Cystectomy
5%
Keyphrases
Prostate-specific Antigen
61%
Prostate Cancer
59%
18F-DCFPyL
46%
Positron Emission Tomography-computed Tomography (PET-CT)
35%
Renal Cell Carcinoma
27%
Tumor
26%
Radiotracer
23%
Small Renal Mass
22%
Partial Nephrectomy
21%
Active Surveillance
21%
Renal Mass
16%
Radical Prostatectomy
16%
PET Imaging
15%
Positron Emission Tomography
15%
Transperineal Prostate Biopsy
14%
Prostate Biopsy
14%
99mTc-sestamibi
13%
Molecular Imaging
12%
Renal Tumor
12%
Oncological Outcomes
11%
Radical Nephrectomy
11%
Reporting System
11%
Multiparametric MRI (mpMRI)
10%
Confidence Interval
9%
Conventional Imaging
9%
Oligometastatic Prostate Cancer
9%
Clinically Significant Prostate Cancer
8%
Tumor Thrombus
8%
Data Systems
8%
Circulating Tumor Cells
8%
Clear Cell Renal Cell Carcinoma (ccRCC)
7%
Recurrent Prostate Cancer
7%
Metastatic Renal Cell Carcinoma (mRCC)
7%
Renal Mass Biopsy
7%
Bladder Cancer
7%
SPECT-CT
7%
Grade Group
7%
Meta-analysis
6%
Robot-assisted Partial Nephrectomy
6%
Overall Survival
6%
Transperineal
6%
Systematic Meta-analysis
6%
Delayed Intervention
6%
Chromophobe
6%
Single-photon Emission Computed Tomography (SPECT)
6%
Inferior Vena Cava
6%
Oncocytic Variant
6%
Nephrectomy
5%
Infectious Complications
5%
Focal Therapy
5%